Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Keith T. Flaherty, Yoshiyasu Umeda et al.|EClinicalMedicine|2023Cited by 26